

Ref: FOI/2025/11304

Date Received: 17th December 2025

Response Due: 19th January 2026

Date: 31st December 2025

Dear Sir/Madam

With reference to your request for information received on 17th December 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold the information you have requested. A response to each part of your request is provided below.

In your request you asked:

- 1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.**

90 patients in total, including patients who may only be on zoledronic acid.

83 patients on SACT including any of the drugs listed below.

- 2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:**

- Belantamab Mafodotin [Blenrep] = 1.
- Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone = 0.
- Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone = 0.
- Bortezomib [Velcade] ± Dexamethasone = 0.
- Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd) = 1.
- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) = 0.
- Carfilzomib [Kyprolis] + Dexamethasone = 4.
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) = 0.
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) = 19.
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) = 5.
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) = 15.
- Daratumumab [Darzalex] monotherapy = 4.
- Elranatamab = 2.
- Idecabtagene vicleucel [Abecma] = 0.

- Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) = 1.
- Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd) = 0.
- Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd) = 5.
- Lenalidomide [Revlimid] + Dexamethasone = 0.
- Lenalidomide [Revlimid] monotherapy = 14.
- Panobinostat + Bortezomib + Dexamethasone = 0.
- Pomalidomide [Imnovid] + Dexamethasone = 3.
- Selinexor + Bortezomib [Velcade] + Dexamethasone = 0.
- Selinexor + Dexamethasone = 0.
- Talquetamab = 0.
- Teclistamab [Tecvayli] = 0.
- Any other systemic anti-cancer therapy [please specify] = please see the below.
 - Cyclophosphamide orally = 3.
 - Thalidomide maintenance = 1.

3. In the last 6 months, how many patients have been initiated* on the following regimens?

- Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD) = 0.
- Carfilzomib [Kyprolis] + Dexamethasone = 1.
- Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd) = 0.
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd) = 2.
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd) = 0.
- Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd) = 4.
- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd) = 6.
- Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd) = 1.
- Lenalidomide [Revlimid] monotherapy = 0.
- Lenalidomide [Revlimid] + Dexamethasone = 0.
- Selinexor + Bortezomib [Velcade] + Dexamethasone = 0.
- Selinexor + Dexamethasone = 0.
- Any other systemic anti-cancer therapy [please specify] = 5 – please see the below.
 - Pomalidomide = 1.
 - Belantamab = 1.
 - Cyclophosphamide = 3.

***Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation.**

4. In the last 6 months, how many patients have received the following second-line treatment?

- Lenalidomide [Revlimid] + Dexamethasone = 0.

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Masterman', with a horizontal line extending from the end.

Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111